Lysophosphatidic Acid Receptor-2 Deficiency Confers Protection Against Bleomycin-induced Lung Injury and Fibrosis in Mice
Overview
Molecular Biology
Authors
Affiliations
Idiopathic pulmonary fibrosis is a devastating disease characterized by alveolar epithelial cell injury, the accumulation of fibroblasts/myofibroblasts, and the deposition of extracellular matrix proteins. Lysophosphatidic acid (LPA) signaling through its G protein-coupled receptors is critical for its various biological functions. Recently, LPA and LPA receptor 1 were implicated in lung fibrogenesis. However, the role of other LPA receptors in fibrosis remains unclear. Here, we use a bleomycin-induced pulmonary fibrosis model to investigate the roles of LPA2 in pulmonary fibrogenesis. In the present study, we found that LPA2 knockout (Lpar2(-/-)) mice were protected against bleomycin-induced lung injury, fibrosis, and mortality, compared with wild-type control mice. Furthermore, LPA2 deficiency attenuated the bleomycin-induced expression of fibronectin (FN), α-smooth muscle actin (α-SMA), and collagen in lung tissue, as well as levels of IL-6, transforming growth factor-β (TGF-β), and total protein in bronchoalveolar lavage fluid. In human lung fibroblasts, the knockdown of LPA2 attenuated the LPA-induced expression of TGF-β1 and the differentiation of lung fibroblasts to myofibroblasts, resulting in the decreased expression of FN, α-SMA, and collagen, as well as decreased activation of extracellular regulated kinase 1/2, Akt, Smad3, and p38 mitogen-activated protein kinase. Moreover, the knockdown of LPA2 with small interfering RNA also mitigated the TGF-β1-induced differentiation of lung fibroblasts. In addition, LPA2 deficiency significantly attenuated the bleomycin-induced apoptosis of alveolar and bronchial epithelial cells in the mouse lung. Together, our data indicate that the knockdown of LPA2 attenuated bleomycin-induced lung injury and pulmonary fibrosis, and this may be related to an inhibition of the LPA-induced expression of TGF-β and the activation and differentiation of fibroblasts.
Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF).
Aribindi K, Liu G, Albertson T Expert Rev Clin Pharmacol. 2024; 17(9):817-835.
PMID: 39192604 PMC: 11441789. DOI: 10.1080/17512433.2024.2396121.
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis.
Volkmann E, Denton C, Kolb M, Wijsenbeek-Lourens M, Emson C, Hudson K Eur Respir Rev. 2024; 33(172).
PMID: 39009409 PMC: 11262619. DOI: 10.1183/16000617.0015-2024.
Zhou Q, Chen Y, Liang Y, Sun Y Metabolites. 2024; 14(6).
PMID: 38921452 PMC: 11205356. DOI: 10.3390/metabo14060317.
Du M, Liu K, Lai H, Qian J, Ai L, Zhang J Bioact Mater. 2024; 36:358-375.
PMID: 38496031 PMC: 10944202. DOI: 10.1016/j.bioactmat.2024.03.005.
Yoon D, Choi B, Kim J, Kim E, Chung S, Min H BMC Med. 2024; 22(1):122.
PMID: 38486246 PMC: 10941471. DOI: 10.1186/s12916-024-03342-x.